PIRS Dana dhuwit perusahaan Pieris Pharmaceuticals, Inc.

Logo perusahaan publik pieris.com (PIRS)

Pieris Pharmaceuticals (PIRS) faces significant business risks due to a capital shortage and potential research failures. The cash balance shown on the GURU.Markets temporary chart confirms this trend, with the metric currently standing at 0.26. Anticalin protein patents and lobbying efforts serve as a defense, despite strict FDA oversight. However, the severance of ties with industry behemoths has triggered a prolonged liquidity crisis.

Pieris - Sisa dhuwit perusahaan PIRS (periode 04.07.2022 - 21.11.2026)

Rincian metrik keuangan lan pasar Pieris Pharmaceuticals, Inc. (PIRS)

- kuotasi lan prakiraan analis:
Analisis komprehensif perusahaan:PIRS Pieris Pharmaceuticals
Produk merek pieris.com

Global scaling of the Anticalin protein platform requires colossal expenditures on clinical trials and B2B partnerships. This metric measures the volume of liquid assets, determining the ability of Pieris Pharmaceuticals (PIRS) to finance expansion without external borrowing. By analyzing the cash flow chart on GURU.Markets, an investor assesses the burn rate. Liquidity dynamics directly confirm the issuer's solvency. A stable cash balance guarantees the fundamental stability of the asset.

Pesaing langsung

Dana dhuwit perusahaan Haleon (HLN)|Volume dana dhuwit perusahaan Kenvue Inc. (KVUE)|Volume dana dhuwit perusahaan VRNA (veronapharma.com)|Sisa dhuwit perusahaan MENS|LGND: Dhuwit awis perusahaan|Sisa dhuwit perusahaan AMRX (Amneal Corp)|PRGO (Perrigo Company plc) - Dhuwit awis perusahaan|Alvotech - Sisa dhuwit perusahaan|Dhuwit awis perusahaan LQDA|Galapagos Genomics (GLPG) - Aset likuid perusahaan|Volume dana dhuwit perusahaan ANIP|Dhuwit awis perusahaan Afrezza MNKD|Dana dhuwit perusahaan Amphastar AMPH|Aset likuid perusahaan Pacira BioSciences (PCRX)|ARS Corp - Volume dana dhuwit perusahaan|TBPH: Dana dhuwit perusahaan|AQST: Volume dana dhuwit perusahaan|SCPH - Aset likuid perusahaan|TECX (Tectonic) - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Tonix Pharmaceuticals Holding Corp. TNXP|Dana dhuwit perusahaan SXT Pharmaceuticals (SXTC)|Volume dana dhuwit perusahaan Eupraxia Pharmaceuticals Inc. (EPRX)|Dana dhuwit perusahaan BioHarvest Sciences BHST|EXOZ (Invizyne) - Total volume dana dhuwit perusahaan|ORMP: Dhuwit awis perusahaan|ENTX (Entera Bio Ltd) - Dhuwit awis lan setara dhuwit awis perusahaan|HYFT: Volume dana dhuwit perusahaan|Dhuwit awis perusahaan ABVC BioPharma Inc.|CPIX (cumberlandpharma.com) - Volume dana dhuwit perusahaan|Dana dhuwit perusahaan QNTM|Volume dana dhuwit perusahaan FGEN|Dhuwit awis perusahaan Telomir Pharmaceuticals TELO|Volume dana dhuwit perusahaan RANI (ranitherapeutics.com)|SNYR (Synergy CHC Corporation) - Total volume dana dhuwit perusahaan|RLYB - Dana dhuwit perusahaan|LEXX (Lexaria Bioscience Corp.) - Dhuwit awis lan setara dhuwit awis perusahaan|pulmatrix.com (PULM) - Dana dhuwit perusahaan|PTHL (Pheton) - Dana dhuwit perusahaan|Dana dhuwit perusahaan Aptorum|Cadangan dhuwit perusahaan Lyra Therapeutics Inc. LYRA|Volume dana dhuwit perusahaan IBO|TNFA (TNF Pharmaceuticals, Inc.) - Sisa dhuwit perusahaan|Dana dhuwit perusahaan cbdMD, Inc. YCBD|Sisa dhuwit perusahaan PRFX|Altamira Therapeutics Ltd. - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Lipella Pharmaceuticals Inc|OPTN: Volume dana dhuwit perusahaan|Procaps Group S.A. (PROC) - Volume dana dhuwit perusahaan|PTPI (Petros Pharma) - Volume dana dhuwit perusahaan|QLI: Sisa dhuwit perusahaan|Volume dana dhuwit perusahaan SLRN|TFFP (TFF Pharmaceuticals Inc.) - Sisa dhuwit perusahaan